Basilea pharma - Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL!
Basilea pharma (BSLN) along with its partner, Astellas is co-developing antifungal Isavuconazole (PhIII) for invasive fungal infections. Isavuconazole demonstrated non-inferiority vs. voriconazole in its international PhIII, SECURE trial in pts (n = 516) with invasive fungal disease caused by Aspergillus species or certain other filamentous fungi. Both intravenous (IV) and oral formulation of Isavuconazole offer flexible dosing options, in addition to a broad spectrum of activity and thus, it may offer potential benefits over the current gold standard (Vfend, Cancidas). With an increasing rate of serious infections and resistance to current drugs, we. For more detail, please read our report, released on 30th Sept., 2013 on BSLN, titled, 'Isavuconazole SECUREs Primary endpoint – Watch out for ACTIVE and VITAL! '
